Dexmedetomidine as an Adjuvant to Greater Auricular Nerve Block in Middle Ear Surgeries
Sponsor: Minia University • ClinicalTrials.gov ID: NCT07878533
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
This randomized, double-blind, controlled study will evaluate whether adding dexmedetomidine to bupivacaine in an ultrasound-guided greater auricular nerve block prolongs pain relief after middle ear surgery. Adults undergoing elective middle ear surgery under general anesthesia will receive the block before induction, either with bupivacaine alone or with bupivacaine plus dexmedetomidine. The main outcome is how long pain relief lasts after the block. Other outcomes include pain scores, opioid use, emergence agitation, hemodynamic changes, and side effects.
Interventions
-
Bupivacaine
(Drug)
2 ml of bupivacaine 0.25% injected around the greater auricular nerve under ultrasound guidance before induction of general anesthesia.
-
Dexmedetomidine
(Drug)
1 ml of dexmedetomidine 0.5 µg/kg added to bupivacaine in the greater auricular nerve block.
-
Normal saline
(Drug)
1 ml of normal saline 0.9% added to 2 ml bupivacaine 0.25% in the greater auricular nerve block.
-
Ultrasound-guided greater auricular nerve block
(Procedure)
Ultrasound-guided block of the greater auricular nerve performed before induction of general anesthesia in both groups.
Eligibility criteria
Conditions
Locations
- Minia university hospital — Minya, Egypt
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record